NanoRetinal Secures Rare Disease Evidence Principles (RDEP) Pathway from CDER Ophthalmology at FDA
NAR-001 in RLBP1-associated Inherited Retinal Disease admitted to RDEP Princeton, N.J., Nov. 19, 2026 (GLOBE NEWSWIRE) -- The U.S. Food and Drug Administration’s (FDA) Center for Drug Evaluation and Research (CDER) announced recently that NanoRetinal, Inc., a biotechnology…
